Liletta (Levonorgestrel) Patent Expiration, LOE Window & CMS Spending

Liletta (Levonorgestrel) by Medicines360: FDA Orange Book core substance LOE 2033-10-06 (last listed 2040-09-07), 0 AB generics, $20.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMedicines360
FDA Application & PathwayN206229 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-10-06
Last Listed Patent or Exclusivity Date2040-09-07
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$20.1M
2024 Medicare Part D Spend$30K
2024 Medicaid Spend$20.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel